secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2025-04-01T23:59:59+00:00
Accession:  0001558370-25-004264
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus to repurchase $170M of convertible notes, conditional on UDENYCA sale close
--------------------------------------------------------------------------------

- Coherus agreed to repurchase ~$170M aggregate principal of its 1.500% Convertible Notes due 2026 at 100% par plus accrued interest.
- Repurchases conditioned on closing of UDENYCA franchise divestiture to Intas Pharmaceuticals, expected early Q2 2025.
- After repurchase, ~$60M of notes remain; Coherus plans a repurchase offer for those notes post-close.
- Holders representing a majority of outstanding notes consented to indenture amendments permitting the UDENYCA divestiture.
- Amendments executed via supplemental indenture dated March 31, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000155837025004264/0001558370-25-004264-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000155837025004264/chrs-20250331x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-004264

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer